Auvelity and Weight Loss
Auvelity (dextromethorphan/bupropion) is not indicated for weight loss and should not be prescribed for this purpose. This medication is FDA-approved exclusively for the treatment of major depressive disorder in adults 1.
Why This Matters
While Auvelity contains bupropion—a component that has been associated with modest weight loss when used alone or in combination with naltrexone (Contrave)—the dextromethorphan/bupropion formulation in Auvelity was developed and studied specifically for depression, not obesity management 2, 3.
The Evidence on Bupropion and Weight
Bupropion monotherapy has demonstrated consistent weight loss effects across multiple studies:
- Bupropion alone produces approximately 2.8 kg weight loss at 6-12 months 4
- It is the only antidepressant consistently associated with weight loss or weight neutrality 5, 6
- Historical data show bupropion at 50-450 mg/day was associated with 1-2 pound weight loss, compared to 3-9 pound weight gain with amitriptyline 7
Bupropion/naltrexone combination (Contrave) is FDA-approved specifically for chronic weight management and produces greater weight loss than bupropion alone 8.
Critical Distinctions
Why Auvelity Is Different
Wrong formulation: Auvelity contains dextromethorphan (an NMDA receptor antagonist) combined with bupropion, not the naltrexone combination proven for weight loss 2
Wrong indication: Clinical trials for Auvelity focused on depression outcomes (Montgomery-Åsberg Depression Rating Scale scores), not weight loss 3
Safety concerns: Auvelity carries significant contraindications including seizure disorders, eating disorders (anorexia nervosa, bulimia), and multiple drug interactions 1
Cost barrier: Auvelity costs approximately $1,119 per month compared to generic bupropion at $18/month 9
If Weight Loss Is the Goal
For patients with obesity (BMI ≥30) or overweight with complications (BMI ≥27), consider FDA-approved weight loss medications:
- Bupropion/naltrexone SR (Contrave): Produces modest weight loss through synergistic effects on POMC neurons 8
- Phentermine/topiramate ER: 9.2% total body weight loss 8
- Liraglutide 3.0 mg: Significant weight loss with metabolic benefits 8
- Semaglutide 2.4 mg: 10.3-12.4% total body weight loss 10, 11
All weight loss medications should be combined with lifestyle modifications (diet and exercise) and discontinued if weight loss goals are not met at specified timepoints 4, 8.
Common Pitfall to Avoid
Do not prescribe Auvelity off-label for weight loss. The presence of bupropion in the formulation does not make it appropriate for obesity management. The medication was not studied for this indication, carries unnecessary risks (particularly the dextromethorphan component), and is prohibitively expensive compared to proven alternatives 1, 9.
If a patient has both depression and obesity, consider bupropion monotherapy for depression (which may provide modest weight benefit) or, if appropriate, bupropion/naltrexone specifically approved for weight management in patients who also have depressive symptoms 8, 5.